Seer to Present at the J.P. Morgan 41st Annual Health Care Conference
December 27 2022 - 4:05PM
Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing
a disruptive new platform for proteomics, today announced that the
company will be participating in the upcoming 41st Annual J.P.
Morgan Healthcare Conference.
Seer’s management is scheduled to present and
participate in a Q&A session on Tuesday, January 10th at 3:00
p.m. Pacific Time / 6:00 p.m. Eastern Time. A live webcast of the
session will be available on the Investor section of Seer’s website
at investor.seer.bio. An archived replay will be available on the
company’s website following the conference.
About Seer Seer is a life sciences company
developing transformative products that open a new gateway to the
proteome. Seer’s Proteograph™ Product Suite is an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Investor ContactCarrie
Mendivilinvestor@seer.bio
Media ContactKaren Possematopr@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024